Merck & Co will pay up to $773m to acquire biopharmaceutical developer Tilos Therapeutics, based on research at Harvard Medical School and Brigham & Women’s Hospital.
Tilos Therapeutics, a US-based biopharmaceutical company advancing research from Harvard University and Brigham & Women’s Hospital, yesterday agreed to an acquisition worth up to $773m by pharmaceutical group Merck & Co.
Merck will, through an unnamed subsidiary, purchase all outstanding shares in Tilos and make an upfront payment, with additional contingent milestone payments. Details of the size of each part of the deal were not disclosed.
Founded in 2016, Tilos is developing treatments targeting TGFβ, a small protein…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
